Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.56 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5460102 | 0.87 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11HRH4 | |
| SCHEMBL5875497 | 0.81 | MAPK14 (0.61) | MAPK14ADORA2AADORA2BADORA1GRIA1 | |
| SCHEMBL5378779 | 0.81 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11ADORA2A | |
| SCHEMBL5463256 | 0.81 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11ADORA2A | |
| SCHEMBL5455979 | 0.79 | MAPK14 (0.44) | MAPK14ADORA2AADORA2BADORA1GRIA1 | |
| SCHEMBL5382408 | 0.79 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11ADORA2A | |
| SCHEMBL5387834 | 0.78 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11ADORA2A | |
| SCHEMBL5875504 | 0.77 | MAPK14 (0.77) | MAPK14ADORA2AADORA2BADORA1 | |
| SCHEMBL5379033 | 0.75 | MAPK14 (0.58) | MAPK14MAPK10MAPK13MAPK12MAPK11 | |
| SCHEMBL5448895 | 0.75 | MAPK14 (0.61) | MAPK14ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109209-B2 | Pyrazolopyridines, process for their preparation and use as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-19 | — | — | US | claimed |
| US-7034030-B2 | Pyralopyridines, process for their preparation and use as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| US-20060058319-A1 | Pyrazolopyridines, process for their preparation and use as therapeutic compounds | ALBERTI MICHAEL J | 2006-03-16 | — | — | US | disclosed |
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058319-A1 | Pyrazolopyridines, process for their preparation and use as therapeutic compounds | CYP3A5, CYP3A4, CYP3A7 | MAPK14 2256/4885MAPK10 2405/4885MAPK13 1593/4885 |
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | QDPR, DPYD, ENTPD5 | MAPK14 1551/4885MAPK10 2996/4885MAPK13 2280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.